MDG1.F Medigene AG (XETRA) up 8.09% pre-market 26 Feb 2026: monitor liquidation updates
MDG1.F stock rises 8.09% pre-market to €0.037; analysis, Meyka grade and forecast for Medigene AG on XETRA
MDG1.F stock rises 8.09% pre-market to €0.037; analysis, Meyka grade and forecast for Medigene AG on XETRA
Hino-cho case retrial triggers Japan retrial reform debate. We explain the Supreme Court Japan ruling, likely changes on disclosure and wrongful conviction compensation, and investor risks.
Intraday report: 5LY.SI stock fell 7.98% to S$0.163 on 26 Feb 2026. Short-term outlook and Meyka AI forecast included.
EEL.AX stock jumps 50.0% to A$0.0015 on heavy volume; short-term outlook and Meyka AI forecast included
Nancy Pelosi returns to focus as Trump urges the Stop Insider Trading Act. What it means for Congress stock trading ban efforts and Canadian investors watching U.S. policy risk.
CGNX stock pre-market at $57.88 on 26 Feb 2026. Analyst targets, valuation, and Meyka AI forecast for short-term AI demand.
Raymond James keeps Outperform on Par Pacific; PARR analyst rating stays Outperform with $50.00 price target
Goldman Sachs upgraded Allegro.eu SA on Feb 25, 2026. Read the ALEGF analyst rating change, market impact, and Meyka AI grade B
Intraday volume spike lifts SICAL.NS stock to INR 129.41 on 26 Feb 2026; targets, risks and Meyka AI forecast inside
Ofgem price cap cut 7% from April to £1,641. What this means for UK energy bills, the UK inflation outlook, and how Japan-based investors can position today.